Unknown

Dataset Information

0

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.

ABSTRACT: Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.

SUBMITTER: Nyland SB 

PROVIDER: S-EPMC3312981 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.

Nyland Susan Bell SB   Krissinger Daniel J DJ   Clemente Michael J MJ   Irby Rosalyn B RB   Baab Kendall Thomas KT   Jarbadan Nancy Ruth NR   Sokol Lubomir L   Schaefer Eric E   Liao Jason J   Cuthbertson David D   Epling-Burnette Pearlie P   Paquette Ronald R   List Alan F AF   Maciejewski Jaroslaw P JP   Loughran Thomas P TP  

Leukemia research 20120302 5

Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera  ...[more]

Similar Datasets

Unknown Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation.
| S-EPMC7546795 | biostudies-literature
Unknown Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.
| S-EPMC8550969 | biostudies-literature
Unknown P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
| S-EPMC10430663 | biostudies-literature
Unknown Aplastic anemia and paroxysmal nocturnal hemoglobinuria in children and adults in two centers of Northern Greece.
| S-EPMC9684709 | biostudies-literature
Unknown Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH).
| S-EPMC7495826 | biostudies-literature
Unknown Paroxysmal nocturnal hemoglobinuria-phenotype cells predict a good response to eltrombopag in patients with refractory aplastic anemia.
| S-EPMC9175921 | biostudies-literature
Unknown Paroxysmal nocturnal hemoglobinuria.
| S-EPMC4215311 | biostudies-literature
Unknown Leukemia evolving from paroxysmal nocturnal hemoglobinuria.
| S-EPMC8672449 | biostudies-literature
Unknown Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria.
| S-EPMC6023248 | biostudies-literature
Unknown DIAGNOSTIC DILEMMAS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA.
| S-EPMC5529684 | biostudies-literature